New York State Common Retirement Fund’s Day One Biopharmaceuticals DAWN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-24,732
| Closed | -$530K | – | 3211 |
|
|
2026
Q1 | $530K | Buy |
24,732
+12,600
| +104% | +$178K | ﹤0.01% | 1883 |
|
|
2025
Q4 | $113K | Hold |
12,132
| – | – | ﹤0.01% | 2547 |
|
|
2025
Q3 | $85.5K | Hold |
12,132
| – | – | ﹤0.01% | 2701 |
|
|
2025
Q2 | $78.9K | Hold |
12,132
| – | – | ﹤0.01% | 2809 |
|
|
2025
Q1 | $96.2K | Hold |
12,132
| – | – | ﹤0.01% | 2535 |
|
|
2024
Q4 | $154K | Hold |
12,132
| – | – | ﹤0.01% | 2417 |
|
|
2024
Q3 | $169K | Sell |
12,132
-7,900
| -39% | -$113K | ﹤0.01% | 2380 |
|
|
2024
Q2 | $276K | Sell |
20,032
-46,196
| -70% | -$676K | ﹤0.01% | 2288 |
|
|
2024
Q1 | $1.09M | Sell |
66,228
-12,071
| -15% | -$181K | ﹤0.01% | 1733 |
|
|
2023
Q4 | $1.14M | Buy |
78,299
+13,294
| +20% | +$161K | ﹤0.01% | 1731 |
|
|
2023
Q3 | $798K | Sell |
65,005
-8,061
| -11% | -$105K | ﹤0.01% | 1859 |
|
|
2023
Q2 | $872K | Buy |
73,066
+18,831
| +35% | +$246K | ﹤0.01% | 1840 |
|
|
2023
Q1 | $725K | Buy |
54,235
+2,422
| +5% | +$47.3K | ﹤0.01% | 1983 |
|
|
2022
Q4 | $1.12M | Buy |
51,813
+23
| +0% | +$472 | ﹤0.01% | 1914 |
|
|
2022
Q3 | $1.04M | Buy |
51,790
+32,322
| +166% | +$687K | ﹤0.01% | 1952 |
|
|
2022
Q2 | $348K | Buy |
19,468
+58
| +0.3% | +$599 | ﹤0.01% | 2526 |
|
|
2022
Q1 | $193K | Buy |
19,410
+11,308
| +140% | +$149K | ﹤0.01% | 2832 |
|
|
2021
Q4 | $137K | Buy |
+8,102
| New | +$167K | ﹤0.01% | 2996 |
|
Other funds holding DAWN
New York State Common Retirement Fund's DAWN Position: Q2 2026 in Review
New York State Common Retirement Fund sold out of Day One Biopharmaceuticals (DAWN) in Q2 2026, closing a stake of 24,732 shares — an estimated $530K sold.
New York State Common Retirement Fund first reported a position in DAWN in Q4 2021 and held it in 18 quarters. The position peaked at $1.14M in Q4 2023. 1 fund tracked by Wall St. Rank holds DAWN as of Q2 2026.
- New York State Common Retirement Fund reported no remaining Day One Biopharmaceuticals position as of Q2 2026 after selling out during the quarter.
- New York State Common Retirement Fund sold 24,732 Day One Biopharmaceuticals shares in Q2 2026, an estimated $530K.
- New York State Common Retirement Fund first reported a position in Day One Biopharmaceuticals in Q4 2021 and held it in 18 quarters.
- New York State Common Retirement Fund's Day One Biopharmaceuticals position peaked at $1.14M in Q4 2023.
- 1 fund tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q2 2026.
Based on New York State Common Retirement Fund's 13F filing for Q2 2026, filed 29 Jul 2026.